Summary
Danish pharma giant Novo Nordisk is under intense pressure today after its highprofile Alzheimers trials for semaglutide failed, sending the stock to multiyear lows and capping a brutal year for NVO shareholders.
Novo Nordisk stock today: how far has NVO fallen?
Novo Nordisks Alzheimers setba…
Source: ts2.tech
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
